Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.69
BCR's Cash to Debt is ranked higher than
65% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. BCR: 0.69 )
BCR' s 10-Year Cash to Debt Range
Min: 0.06   Max: No Debt
Current: 0.69

Equity to Asset 0.36
BCR's Equity to Asset is ranked higher than
53% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. BCR: 0.36 )
BCR' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.77
Current: 0.36

0.33
0.77
Interest Coverage 26.96
BCR's Interest Coverage is ranked higher than
68% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. BCR: 26.96 )
BCR' s 10-Year Interest Coverage Range
Min: 5   Max: 56.91
Current: 26.96

5
56.91
F-Score: 8
Z-Score: 4.19
M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 51.36
BCR's Operating margin (%) is ranked higher than
99% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. BCR: 51.36 )
BCR' s 10-Year Operating margin (%) Range
Min: 13.55   Max: 39.79
Current: 51.36

13.55
39.79
Net-margin (%) 25.49
BCR's Net-margin (%) is ranked higher than
98% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.99 vs. BCR: 25.49 )
BCR' s 10-Year Net-margin (%) Range
Min: 5.96   Max: 22.62
Current: 25.49

5.96
22.62
ROE (%) 45.19
BCR's ROE (%) is ranked higher than
99% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. BCR: 45.19 )
BCR' s 10-Year ROE (%) Range
Min: 12.31   Max: 44.24
Current: 45.19

12.31
44.24
ROA (%) 17.02
BCR's ROA (%) is ranked higher than
98% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. BCR: 17.02 )
BCR' s 10-Year ROA (%) Range
Min: 5.54   Max: 21.39
Current: 17.02

5.54
21.39
ROC (Joel Greenblatt) (%) 193.77
BCR's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. BCR: 193.77 )
BCR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 30.52   Max: 143.53
Current: 193.77

30.52
143.53
Revenue Growth (%) 9.50
BCR's Revenue Growth (%) is ranked higher than
83% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. BCR: 9.50 )
BCR' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 13.9
Current: 9.5

-1.5
13.9
EBITDA Growth (%) 25.20
BCR's EBITDA Growth (%) is ranked higher than
90% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. BCR: 25.20 )
BCR' s 10-Year EBITDA Growth (%) Range
Min: -18.5   Max: 41
Current: 25.2

-18.5
41
EPS Growth (%) 16.70
BCR's EPS Growth (%) is ranked higher than
85% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. BCR: 16.70 )
BCR' s 10-Year EPS Growth (%) Range
Min: -14.8   Max: 43.2
Current: 16.7

-14.8
43.2
» BCR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BCR Guru Trades in Q4 2013

Paul Tudor Jones 2,600 sh (New)
Vanguard Health Care Fund 303,700 sh (New)
Jim Simons 664,300 sh (+39.24%)
Pioneer Investments 990,073 sh (+0.09%)
Jeremy Grantham 105,513 sh (-9.43%)
Yacktman Fund 3,500,000 sh (-9.89%)
Chuck Royce 55,200 sh (-10%)
Joel Greenblatt 14,152 sh (-11.18%)
RS Investment Management 30,670 sh (-11.38%)
Robert Olstein 35,000 sh (-14.63%)
Steven Cohen 16,416 sh (-15.84%)
Donald Yacktman 7,755,464 sh (-21.46%)
Yacktman Focused Fund 3,000,000 sh (-29.91%)
Ray Dalio 19,786 sh (-30.54%)
» More
Q1 2014

BCR Guru Trades in Q1 2014

Vanguard Health Care Fund 1,839,200 sh (+505.6%)
Ray Dalio 43,186 sh (+118.27%)
Jeremy Grantham 199,094 sh (+88.69%)
Paul Tudor Jones 4,000 sh (+53.85%)
RS Investment Management 33,675 sh (+9.8%)
Chuck Royce Sold Out
Joel Greenblatt 13,984 sh (-1.19%)
Pioneer Investments 968,763 sh (-2.15%)
Yacktman Fund 3,424,600 sh (-2.15%)
Donald Yacktman 6,827,627 sh (-11.96%)
Robert Olstein 30,000 sh (-14.29%)
Yacktman Focused Fund 2,350,000 sh (-21.67%)
Jim Simons 463,600 sh (-30.21%)
Steven Cohen 2,314 sh (-85.9%)
» More
Q2 2014

BCR Guru Trades in Q2 2014

Louis Moore Bacon 2,675 sh (New)
Joel Greenblatt 40,174 sh (+187.29%)
Robert Olstein 38,000 sh (+26.67%)
Paul Tudor Jones 4,500 sh (+12.5%)
Jeremy Grantham 212,394 sh (+6.68%)
RS Investment Management Sold Out
Pioneer Investments 962,331 sh (-0.66%)
Donald Yacktman 6,701,207 sh (-1.85%)
Yacktman Focused Fund 2,300,000 sh (-2.13%)
Yacktman Fund 3,330,000 sh (-2.76%)
Jim Simons 418,200 sh (-9.79%)
Ray Dalio 27,386 sh (-36.59%)
Vanguard Health Care Fund 1,157,400 sh (-37.07%)
» More
Q3 2014

BCR Guru Trades in Q3 2014

John Hussman 15,000 sh (New)
Joel Greenblatt 229,325 sh (+470.83%)
Ray Dalio 59,086 sh (+115.75%)
Jim Simons 542,100 sh (+29.63%)
Pioneer Investments 962,724 sh (+0.04%)
Louis Moore Bacon Sold Out
Jeremy Grantham 211,694 sh (-0.33%)
Yacktman Fund 3,250,000 sh (-2.4%)
Donald Yacktman 6,443,334 sh (-3.85%)
Yacktman Focused Fund 2,150,000 sh (-6.52%)
Vanguard Health Care Fund 1,039,100 sh (-10.22%)
Robert Olstein 34,000 sh (-10.53%)
Paul Tudor Jones 3,890 sh (-13.56%)
» More
» Details

Insider Trades

Latest Guru Trades with BCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 470.83%0.27%$142.3 - $153.13 $ 171.5816%229325
Yacktman Focused Fund 2014-09-30 Reduce -6.52%0.22%$142.3 - $153.13 $ 171.5816%2150000
John Hussman 2014-09-30 New Buy0.18%$142.3 - $153.13 $ 171.5816%15000
Donald Yacktman 2014-09-30 Reduce -3.85%0.15%$142.3 - $153.13 $ 171.5816%6443334
Ray Dalio 2014-09-30 Add 115.75%0.04%$142.3 - $153.13 $ 171.5816%59086
Vanguard Health Care Fund 2014-06-30 Reduce -37.07%0.28%$136.23 - $149.25 $ 171.5820%1157400
Robert Olstein 2014-06-30 Add 26.67%0.15%$136.23 - $149.25 $ 171.5820%38000
Yacktman Fund 2014-06-30 Reduce -2.76%0.12%$136.23 - $149.25 $ 171.5820%3330000
Joel Greenblatt 2014-06-30 Add 187.29%0.05%$136.23 - $149.25 $ 171.5820%40174
Ray Dalio 2014-06-30 Reduce -36.59%0.02%$136.23 - $149.25 $ 171.5820%27386
Yacktman Focused Fund 2014-03-31 Reduce -21.67%0.91%$125.42 - $146.57 $ 171.5824%2350000
Vanguard Health Care Fund 2014-03-31 Add 505.6%0.63%$125.42 - $146.57 $ 171.5824%1839200
Donald Yacktman 2014-03-31 Reduce -11.96%0.51%$125.42 - $146.57 $ 171.5824%6827627
Ray Dalio 2014-03-31 Add 118.27%0.03%$125.42 - $146.57 $ 171.5824%43186
Yacktman Focused Fund 2013-12-31 Reduce -29.91%1.7%$113.84 - $139.85 $ 171.5830%3000000
Donald Yacktman 2013-12-31 Reduce -21.46%1.09%$113.84 - $139.85 $ 171.5830%7755464
Yacktman Fund 2013-12-31 Reduce -9.89%0.45%$113.84 - $139.85 $ 171.5830%3500000
Vanguard Health Care Fund 2013-12-31 New Buy0.13%$113.84 - $139.85 $ 171.5830%303700
Robert Olstein 2013-12-31 Reduce -14.63%0.11%$113.84 - $139.85 $ 171.5830%35000
Ray Dalio 2013-12-31 Reduce -30.54%0.01%$113.84 - $139.85 $ 171.5830%19786
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on CR Bard Inc

Yacktman Funds Comments on C.R. Bard Inc. - Mar 12, 2014

During the fourth quarter, C.R. Bard Inc’s shares rose sharply as the company received more than $800 million in pre-tax proceeds from a long-running patent lawsuit victory. The company has already used some of the proceeds to make acquisitions and increase its investments in attractive new technologies. We think C.R. Bard Inc. is positioned to be one of the fastest growing health care companies over the next few years.



From Yacktman Funds' 2013 Annual Report - Portfolio Manager's Comments



Check out Donald Yacktman latest stock trades

Yacktman Fund Comments on C.R. Bard Inc. - Jan 30, 2014

C.R. Bard Inc. (BCR)'s shares rose sharply during the quarter as the company received more than $800 million in pre-tax proceeds from a long-running patent lawsuit victory. The company has already used some of the proceeds to make acquisitions and increase its investments in attractive new technologies. We think C.R. Bard Inc. is positioned to be one of the fastest growing health care companies over the next few years.

From the Yacktman Fund (Trades, Portfolio)s' fourth quarter 2013 shareholder update.

Check out Donald Yacktman latest stock trades

Top Ranked Articles about CR Bard Inc

Yacktman Funds Comments on C.R. Bard Inc.
During the fourth quarter, C.R. Bard Inc’s shares rose sharply as the company received more than $800 million in pre-tax proceeds from a long-running patent lawsuit victory. The company has already used some of the proceeds to make acquisitions and increase its investments in attractive new technologies. We think C.R. Bard Inc. is positioned to be one of the fastest growing health care companies over the next few years. Read more...
Yacktman Fund Comments on C.R. Bard Inc.
C.R. Bard Inc. (BCR)'s shares rose sharply during the quarter as the company received more than $800 million in pre-tax proceeds from a long-running patent lawsuit victory. The company has already used some of the proceeds to make acquisitions and increase its investments in attractive new technologies. We think C.R. Bard Inc. is positioned to be one of the fastest growing health care companies over the next few years. Read more...
Weekly Insider Sells Highlight: BCR, GLUU, AMT, APOL, JACK
According to GuruFocus Insider Data, the largest insider sells during the past week were: C.R. Bard Inc., Glu Mobile Inc., American Tower Corp., Apollo Education Group Inc. and Jack in the Box Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 16.50
BCR's P/E(ttm) is ranked higher than
93% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.00 vs. BCR: 16.50 )
BCR' s 10-Year P/E(ttm) Range
Min: 13.82   Max: 80.1
Current: 16.5

13.82
80.1
P/B 7.01
BCR's P/B is ranked higher than
57% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. BCR: 7.01 )
BCR' s 10-Year P/B Range
Min: 3.34   Max: 7.24
Current: 7.01

3.34
7.24
P/S 4.10
BCR's P/S is ranked higher than
65% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. BCR: 4.10 )
BCR' s 10-Year P/S Range
Min: 2.55   Max: 4.66
Current: 4.1

2.55
4.66
PFCF 11.93
BCR's PFCF is ranked higher than
98% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 57.37 vs. BCR: 11.93 )
BCR' s 10-Year PFCF Range
Min: 9.99   Max: 47.48
Current: 11.93

9.99
47.48
EV-to-EBIT 7.96
BCR's EV-to-EBIT is ranked higher than
97% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.42 vs. BCR: 7.96 )
BCR' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 19.5
Current: 7.96

6.8
19.5
PEG 0.84
BCR's PEG is ranked higher than
97% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BCR: 0.84 )
BCR' s 10-Year PEG Range
Min: 0.83   Max: 33.25
Current: 0.84

0.83
33.25
Shiller P/E 30.88
BCR's Shiller P/E is ranked higher than
87% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 139.22 vs. BCR: 30.88 )
BCR' s 10-Year Shiller P/E Range
Min: 19.61   Max: 42.12
Current: 30.88

19.61
42.12
Current Ratio 3.15
BCR's Current Ratio is ranked higher than
78% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. BCR: 3.15 )
BCR' s 10-Year Current Ratio Range
Min: 1.14   Max: 5.88
Current: 3.15

1.14
5.88
Quick Ratio 2.56
BCR's Quick Ratio is ranked higher than
80% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. BCR: 2.56 )
BCR' s 10-Year Quick Ratio Range
Min: 0.62   Max: 4.72
Current: 2.56

0.62
4.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
BCR's Dividend Yield is ranked lower than
82% of the 150 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.46 vs. BCR: 0.50 )
BCR' s 10-Year Dividend Yield Range
Min: 0.49   Max: 1.12
Current: 0.5

0.49
1.12
Dividend Payout 0.08
BCR's Dividend Payout is ranked higher than
97% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BCR: 0.08 )
BCR' s 10-Year Dividend Payout Range
Min: 0.03   Max: 1.32
Current: 0.08

0.03
1.32
Dividend growth (3y) 5.40
BCR's Dividend growth (3y) is ranked higher than
73% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.40 vs. BCR: 5.40 )
BCR' s 10-Year Dividend growth (3y) Range
Min: 3.2   Max: 7.4
Current: 5.4

3.2
7.4
Yield on cost (5-Year) 0.66
BCR's Yield on cost (5-Year) is ranked lower than
74% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.71 vs. BCR: 0.66 )
BCR' s 10-Year Yield on cost (5-Year) Range
Min: 0.64   Max: 1.47
Current: 0.66

0.64
1.47
Share Buyback Rate 5.20
BCR's Share Buyback Rate is ranked higher than
96% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. BCR: 5.20 )
BCR' s 10-Year Share Buyback Rate Range
Min: 5.2   Max: -3.3
Current: 5.2

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.47
BCR's Price/DCF (Projected) is ranked higher than
87% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.64 vs. BCR: 1.47 )
BCR' s 10-Year Price/DCF (Projected) Range
Min: 0.89   Max: 2.26
Current: 1.47

0.89
2.26
Price/Median PS Value 1.15
BCR's Price/Median PS Value is ranked higher than
74% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. BCR: 1.15 )
BCR' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 1.29
Current: 1.15

0.38
1.29
Price/Peter Lynch Fair Value 1.00
BCR's Price/Peter Lynch Fair Value is ranked higher than
97% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BCR: 1.00 )
BCR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4   Max: 8.32
Current: 1

0.4
8.32
Earnings Yield (Greenblatt) 12.60
BCR's Earnings Yield (Greenblatt) is ranked higher than
98% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. BCR: 12.60 )
BCR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.1   Max: 14.7
Current: 12.6

5.1
14.7
Forward Rate of Return (Yacktman) 21.19
BCR's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.33 vs. BCR: 21.19 )
BCR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.7   Max: 23.3
Current: 21.19

-2.7
23.3

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:BR6.Germany,
CR Bard Inc was incorporated in 1923. The Company engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company participates in the markets for vascular, urology, oncology and surgical specialty products. It reports its sales in four major product group categories: vascular, urology, oncology and surgical specialties. The Companys vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include: percutaneous transluminal angioplasty, (PTA) catheters, chronic total occlusion (CTO) catheters, guidewires, fabrics, meshes, introducers and accessories; peripheral vascular stents, covered stents and vascular grafts; vena cava filters; biopsy devices; and electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters. The Companys urology products include basic drainage products, continence products and urological specialty products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. These include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters and enteral feeding devices. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs. The companys soft tissue repair products consist of hernia repair grafts, including both synthetic and natural-tissue configurations, and hernia fixation devices. The Company competes in the therapeutic and diagnostic medical device markets around the world. Its products are distributed domestically directly to hospitals and other healthcare institutions as well as through numerous hospitals/surgical supply and other medical specialty distributors with whom the Company has distribution agreements. The Company is subject to various environmental laws and regulations both within and outside the United States.
» More Articles for BCR

Headlines

Articles On GuruFocus.com
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
Weekly 52-Week Highs Highlight: LBTYK, STZ, FISV, BCR Nov 09 2014 
Dividend Aristocrats In Focus Part 19 of 54: CR Bard Oct 15 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
No More a Simple Distributor Sep 07 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 
CR Bard Focuses on Small to Medium-Sized Deals Apr 04 2014 
Yacktman Funds Comments on C.R. Bard Inc. Mar 12 2014 
Yacktman Fund Comments on C.R. Bard Inc. Jan 30 2014 


More From Other Websites
Bard Judge Says Implant Maker Facing Billions in Verdicts Dec 12 2014
Top Performing Funds: Core Style Straddles The Line Dec 10 2014
Bard Declares Quarterly Dividend Dec 10 2014
Bard Declares Quarterly Dividend Dec 10 2014
12 'financial potholes' to avoid now Dec 10 2014
The Cooper Companies Q4 Earnings, Revenues Lag; Up Y/Y Dec 05 2014
Top Performing Funds: Core Style Straddles The Line Dec 03 2014
Teleflex Partners with Premier to Expand Dialysis Portfolio Dec 03 2014
Henry Schein, Cardinal Health Sign Physician Service Deal Nov 25 2014
BARD C R INC /NJ/ Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation... Nov 21 2014
Invacare (IVC) Down to Strong Sell on Dismal Q3 Results Nov 20 2014
Henry Schein Strong on Healthy Track Record, Fundamentals Nov 20 2014
Bard to Present at the Piper Jaffray Healthcare Conference Nov 19 2014
CR Bard (BCR) Scales 52-Week High on Strong Q3 Results Nov 19 2014
LabCorp Shows Strength on Covance Buyout Plan, Robust Q3 Nov 17 2014
Cramer: Stocks That Stand Out Nov 17 2014
MWI Veterinary Beats Q4 Earnings & Sales yet Shares Fall Nov 12 2014
Henry Schein Tops Q3 Earnings, Revenues; Shares Rally Nov 11 2014
Steris Gains on Q2 Earnings and Revenue Beat; EPS View Up Nov 11 2014
CareFusion Q1 Earnings, Revenues Rise and Beat Estimates Nov 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK